TNYA
Tenaya Therapeutics, Inc.
Biotechnology · Healthcare · United States
0.37
close · 2026-10-30
value
2
cheaper than peers2
quality
19
stronger fundamentals19
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 1.19× | 82 |
| price to sales | 62.73× | 19 |
| cash flow yield, latest year | -82.3% | 11 |
| cash flow yield, 3 years ago | -149.3% | 10 |
| cash flow yield, 1 year ago | -109.3% | 7 |
| cash flow yield, 2 years ago | -123.4% | 7 |
| earnings yield, latest year | -160.6% | 6 |
| earnings yield, 1 year ago | -356.6% | 5 |
| earnings yield, 2 years ago | -457.3% | 4 |
| earnings yield, 3 years ago | -751.2% | 2 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 5.7% | 71 |
| return on equity | -121.9% | 19 |
| operating margin | -1882.8% | 12 |
3 of 4 measures available
Facts
| market cap | $84M |
| free cash flow | -$32.6M |
| employees | 70 |
| first trade | 2021-07-30 |
| next earnings | not reported |
| fundamentals updated | 2026-09-01 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.59 | -1.31 | -1.68 | -2.76 |
| free cash flow | -$68.9M | -$91.5M | -$103.3M | -$125.1M |
| net income | -$90.6M | -$111.1M | -$124.1M | -$123.7M |
| revenue | $0 | $0 | $0 | $0 |